← Oncology Approval Tracker

FDA DECISION ·

Opdivo + Yervoy

nivolumab + ipilimumab · Bristol Myers Squibb

Traditional approvalTraditional conversionColorectal cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

For adults and children age 12 years or older with unresectable or metastatic MSI-high or mismatch repair-deficient colorectal cancer.

LAMPGEN ANALYSIS

Why it matters

FDA converted the earlier later-line accelerated use and broadened the label to include first-line treatment of unresectable or metastatic biomarker-selected disease.

What research teams should watch

Obtain mismatch repair or MSI results early and train teams to distinguish immune toxicity from symptoms of advanced colorectal cancer.

PRIMARY RECORDS

Sources